Skip to main
XGN

Exagen Inc (XGN) Stock Forecast & Price Target

Exagen Inc (XGN) Analyst Ratings

Based on 7 analyst ratings
Strong Buy
Strong Buy 71%
Buy 29%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Exagen is a growing medical technology company, with a solid product portfolio of diagnostic testing products that are used for the differential diagnosis, prognosis, and monitoring of rheumatic, autoimmune, and related diseases. The company has a strong track record of revenue growth and profitability, and we expect this trend to continue in the future, driven by market demand for its innovative products and ongoing investments in R&D and sales expansion. Additionally, the company has a focused strategy to increase its ASP and expand its test volume, which we believe will support its long-term growth potential. Despite some near-term headwinds, we believe Exagen's shares are currently undervalued and continue to recommend a BUY rating with a price target of $10.

Bears say

Exagen is facing significant risks in the form of third-party reimbursement issues and limited free cash flow, which are affecting its financial performance and peer valuation. Additionally, the company's reliance on a single operating segment and facility poses operational risks. This, combined with outstanding debt and the potential need for additional capital, leads to a negative outlook on Exagen's stock.

Exagen Inc (XGN) has been analyzed by 7 analysts, with a consensus rating of Strong Buy. 71% of analysts recommend a Strong Buy, 29% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Exagen Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Exagen Inc (XGN) Forecast

Analysts have given Exagen Inc (XGN) a Strong Buy based on their latest research and market trends.

According to 7 analysts, Exagen Inc (XGN) has a Strong Buy consensus rating as of Apr 29, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.86, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.86, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Exagen Inc (XGN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.